Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Clinical Trial ID NCT02032823

PubWeight™ 10.05^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02032823

Top papers